Making use of our proprietary research platform we identified a new genetic biomarker for obesity and also a therapeutic strategy, under our reprofiling approach.
Currently we are conducting a Phase IIa Clinical Trial in order to confirm the specificity of the biomarker GP0044 and validate the efficacy of the compound GPP846 in the target population.
We are also interested in developing a genetic test, preferentially point-of-care, to identify the patients that will mostly benefit from our new targeted therapy for obesity.
We are looking for partners or clients that are interested in proceed with the clinical development of the compound and the development of the genetic test.
